Cytokinetics, Incorporated research snapshot
CYTK AI stock analysis currently reads Cytokinetics, Incorporated as a specialty cardiovascular biotech that has crossed into commercial stage with MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy, while remaining unprofitable and competing with Bristol Myers Squibb Camzyos. At the July 12, 2026 data cutoff, CYTK referenced the July 10 close near $84.87 with a verified market capitalization of about $11.52 billion on 135.77 million shares. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$84.87
Market cap
$11.52 billion
AI score
61 / 100
Rating
Early commercial HCM biotech, launch-sensitive
Trend status
Technical trend bullish near 52-week highs; fundamentals still launch-stage and loss-making
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Cytokinetics sells and partners cardiac myosin medicines. MYQORZO is the first fully commercial product for oHCM, with pipeline options in nHCM, heart failure with reduced ejection fraction (omecamtiv mecarbil), and HFpEF (ulacamten). | High |
| Moat | Moat candidates are cardiac myosin IP, clinical evidence, specialist cardiology relationships, REMS infrastructure, and manufacturing know-how. Competitive intensity versus Camzyos and future labels still tests durability. | Medium |
| Management | Robert I. Blum and team advanced aficamten from late-stage trials through multi-region approvals and a U.S. and EU launch, while raising capital. Ongoing tests are commercial execution, spend control, and capital allocation under high burn. | Medium-high |
| Financial trend | FY2025 revenue was $88.0 million (mostly collaboration and milestones), FY2025 net loss was $785.0 million, and Q1 2026 added $4.8 million of MYQORZO net product revenue in a partial quarter alongside a $206.0 million net loss. | High |
| Valuation | At $84.87, CYTK traded near -13.0x FY2025 EPS of -$6.54 and about 131x FY2025 revenue per share. PE and PB are not useful quality screens while losses and a stockholders deficit persist, so scenarios rest on launch, label expansion, and future earnings power. | Medium |
| Technical trend | Price sat near the top of the 52-week range and above intermediate and long moving-average references, with support near $77 to $82 and resistance near $87 to $88. | Medium |
| Risk level | Main risks are MYQORZO adoption versus Camzyos, REMS and payer access, nHCM regulatory outcomes, high R&D and SG&A burn, convertible and royalty-linked liabilities, dilution, and clinical setbacks in other programs. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech launch and binary regulatory news can move CYTK faster than static models update. | High data confidence |
| Investment certainty | Medium-low certainty. Early commercial traction and positive ACACIA-HCM topline support the thesis, but the stock needs sustained product growth and controlled funding to justify the current capitalization. | Medium-low |
CYTK AI stock forecast
The CYTK AI stock forecast uses scenario ranges around the $84.87 reference and an illustrative three-year profitability proxy because trailing GAAP EPS is still negative. financial_rigor.py three-scenario math with a $2.00 illustrative EPS, growth of 45%/20%/0%, and target PE of 40/25/12 produced about $244 bullish, $86 base, and $24 bearish. Those tool outputs are research bounds, not promises.
$200 to $250
More likely if MYQORZO U.S. and EU adoption outpaces Camzyos, ACACIA-HCM and MAPLE-HCM expand the label and addressable population, operating losses narrow toward sustainable earnings power near the proxy path, and investors keep awarding a premium growth multiple.
$75 to $95
More likely if MYQORZO gains a meaningful but shared oHCM franchise, nHCM progress is gradual, 2026 combined R&D and SG&A stays near the $830 million to $870 million guidance band, and valuation stays close to the current commercial-transition multiple.
$20 to $35
More likely if launch demand stalls, Camzyos or other therapies limit share, payer or REMS friction slows paid scripts, nHCM or pipeline data disappoint, cash burn forces more dilution, or the market re-rates CYTK toward a distressed development multiple.
CYTK AI technical analysis
CYTK AI technical analysis is constructive as of the July 12, 2026 cutoff. Company IR and market quotes put the July 10 close near $84.87, close to the 52-week high near $88.31. Third-party technical sources showed price above the 60-day and 200-day averages, with support near $77 to $82 and resistance near $87 to $88.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $84.87 | July 10, 2026 close from Cytokinetics IR stock info and cross-checked market quotes used for July 12 research and market cap math. |
| Near support | $82 to $83 | Stockinvest listed accumulated-volume support near $82.19; recent pullback lows clustered just under the mid-$80s. |
| Secondary support | $77 to $78 | Intellectia and Stockinvest referenced support near $77.08 to $77.09 as a deeper floor if the $82 area fails. |
| Moving averages | Bullish stack | Intellectia listed MA_20 near $76.88, MA_60 near $72.66, and MA_200 near $65.15, all as Buy references while price stayed above those bands. |
| Resistance | $87 to $88.3 | Stockinvest and Intellectia flagged resistance near $87.26 to $88.25, with the 52-week high near $88.31 as the ceiling reference. |
| Higher resistance | $93 to $99 | Classic pivot extensions and prior upside targets sit in the mid to high $90s if the stock clears the 52-week high on volume. |
| Momentum | Strong but extended | Price is near the top of the 52-week range after a large 2026 advance from the low-$30s area, so momentum is positive and also more sensitive to failed breakouts. |
| Volume | Elevated multi-million share days | Yahoo-style statistics showed multi-million average daily volume; use above-average volume to confirm breakouts beyond $88 or breaks below $77. |
| Volatility | Event-driven biotech | Clinical, regulatory, launch, and financing headlines can produce gaps larger than ordinary technical noise. |
| Invalidation | Decisive close below $77 support | For a trend-following framework, a confirmed break under the $77 zone after holding above the intermediate averages would challenge the bullish technical structure. It is not a personal sell instruction. |
CYTK AI trading strategy
The CYTK AI trading strategy is a rules-based research framework, not personalized advice. It combines live price confirmation with MYQORZO prescriptions and paid-script trends, competition versus Camzyos, cash burn, debt and royalty obligations, share count after financings, FDA calendars, trial data, and EU launch progress.
Wait for CYTK to hold above the intermediate moving-average stack and for any advance beyond the $87 to $88 resistance band to show volume confirmation with an unchanged commercial or pipeline thesis. Check FDA, medical-meeting, and earnings dates before relying on a chart pattern.
Define risk before entry. A failed breakout or decisive close below the $77 support zone can invalidate this setup.
If CYTK pulls back toward $82 or the $77 secondary support band without a negative commercial, clinical, regulatory, or financing update, wait for stabilization and compare the move with MYQORZO paid prescriptions, cash, liabilities, and program timelines.
Do not average down because a share price fell. The setup fails if support breaks alongside weaker demand, adverse data, delayed label expansion, or a higher funding requirement.
Track MYQORZO net product revenue, REMS-certified HCPs, unique prescribers, paid-script mix, EU and China partner progress, MAPLE-HCM PDUFA timing, ACACIA-HCM full data, combined R&D and SG&A versus guidance, cash and investments, convertible notes, term loan, royalty-linked liabilities, diluted shares, and competitor HCM data.
Refresh all scenarios after material earnings, clinical data, an FDA decision, a financing or royalty transaction, a safety signal, or a large price gap. Avoid stale technical levels around binary events.
Investment research summary
Customers and partners pay Cytokinetics for cardiac muscle medicines and related rights. The core economic question is whether MYQORZO can become a durable commercial franchise in HCM and whether later myosin programs can broaden the company beyond a single product story.
Relevant protections are patents, myosin biology know-how, clinical data packages, regulatory exclusivity, REMS and specialty distribution infrastructure, and specialist relationships. Those advantages matter only if MYQORZO shows lasting clinical, access, and economic value versus Camzyos and future alternatives.
The thesis can fail if launch growth slows, Camzyos retains most share, REMS or payer barriers limit paid therapy, nHCM approval is delayed or denied, safety or manufacturing issues appear, cash burn forces repeated dilution, or royalty and debt structures constrain flexibility.
Robert I. Blum led the multi-year aficamten development and commercial readiness path, including multi-region approvals and capital raises such as the May 2026 equity offering. Capital allocation now centers on launch spend, pipeline prioritization, and balance-sheet management under a stockholders deficit.
Targeted therapy for hypertrophic cardiomyopathy and related heart-muscle disease is a multi-year specialty market shaped by diagnosis rates, specialist adoption, REMS complexity, reimbursement, and head-to-head competitive evidence. Success is discontinuous and news-driven rather than smooth.
The verified $11.52 billion market capitalization prices in substantial MYQORZO success plus pipeline optionality. With FY2025 EPS of -$6.54, negative book value, and high 2026 expense guidance, margin of safety cannot be read from traditional PE. It requires conservative assumptions about adoption, competition, spend, financing, and label expansion.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CYTK price and market capitalization | $84.87 close on July 10, 2026; $11.52 billion market capitalization; 135.77 million shares outstanding. financial_rigor.py verified price times shares with a 0.02% difference from the $11.52 billion reported market cap. | Cytokinetics IR stock info, Morningstar/Yahoo share count, verified with financial_rigor.py | July 12, 2026 |
| FY2025 revenue | $88.0 million versus $18.5 million in 2024. Company IR and Macrotrends matched within 0.01%. Revenue included collaboration, technology-transfer, and milestone amounts rather than mature product sales. | Cytokinetics Q4 2025 results, cross-checked with Macrotrends | July 12, 2026 |
| FY2025 net loss | Net loss of $785.0 million, or -$6.54 per share basic and diluted. Company IR and Simply Wall St matched within 0.01%. | Cytokinetics Q4 2025 results, cross-checked with Simply Wall St | July 12, 2026 |
| Q1 2026 revenue, product sales, and net loss | Total revenue $19.4 million, including $4.8 million MYQORZO net product revenue for about nine weeks of U.S. sales; net loss $206.0 million, or -$1.67 per share. | Cytokinetics Q1 2026 results | July 12, 2026 |
| MYQORZO early U.S. launch metrics (as of March 31, 2026) | Over 1,400 HCPs REMS certified; over 275 unique HCPs prescribed MYQORZO; about 680 patients prescribed; over 70% of patients on paid prescription. | Cytokinetics Q1 2026 results | July 12, 2026 |
| Cash, cash equivalents and investments | About $1.1 billion at March 31, 2026 per company narrative; balance-sheet cash and short-term investments plus long-term investments totaled about $1.07 billion. Cross-validation consensus about $1.09 billion with 1.23% source spread. | Cytokinetics Q1 2026 results and condensed balance sheet | July 12, 2026 |
| Debt and related obligations (March 31, 2026) | Current portion of convertible and long-term debt $44.8 million; term loan net $247.2 million; convertible notes net $870.5 million; revenue participation liabilities net $539.1 million; RPI-related liabilities at fair value $138.8 million. Stockholders deficit about $826.6 million. | Cytokinetics Q1 2026 condensed consolidated balance sheet | July 12, 2026 |
| 2026 expense guidance and May 2026 equity financing | GAAP combined R&D and SG&A guidance $830 million to $870 million. May 2026 public offering of 9,859,155 shares at $71.00 for about $700 million gross proceeds before fees, plus underwriter option for 1,478,873 shares. | Cytokinetics Q1 2026 results and May 6, 2026 offering pricing release | July 12, 2026 |
| Pipeline and regulatory calendar | ACACIA-HCM Phase 3 nHCM topline positive on dual primary endpoints; MAPLE-HCM sNDA PDUFA date November 14, 2026; EU launch began in Germany after EC approval; omecamtiv mecarbil COMET-HF and ulacamten AMBER-HFpEF ongoing. | Cytokinetics Q1 2026 results and related IR releases | July 12, 2026 |
| Technical snapshot | Price above MA_20 ~$76.88, MA_60 ~$72.66, and MA_200 ~$65.15; support near $77.08 and $82.19; resistance near $87.26 to $88.25; 52-week range about $32.89 to $88.31. | Intellectia, Stockinvest, and market 52-week quotes | July 12, 2026 |
| Valuation and scenario tool checks | financial_rigor.py PE about -13.0x on FY2025 EPS -$6.54; three-scenario illustrative path with $2.00 EPS proxy, growth 45%/20%/0%, PE 40/25/12 produced about $244 / $86 / $24 over three years. | financial_rigor.py verify-valuation and three-scenario | July 12, 2026 |
This CYTK page is an informational research tool, not investment advice, a recommendation, or a guarantee of performance. Forecast ranges are scenarios based on available dated data and assumptions that can be wrong. Verify live market data and primary filings before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
